Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Pipeline Review, H2 2016

Global Markets Direct’s, ‘Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Pipeline Review, H2 2016’, provides in depth analysis on Focal Adhesion Kinase (FAK or EC 2.7.10.2) targeted pipeline therapeutics.

The report provides comprehensive information on the Focal Adhesion Kinase (FAK or EC 2.7.10.2) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Focal Adhesion Kinase (FAK or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Focal Adhesion Kinase (FAK or EC 2.7.10.2)

The report reviews Focal Adhesion Kinase (FAK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Focal Adhesion Kinase (FAK or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects

The report assesses Focal Adhesion Kinase (FAK or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Focal Adhesion Kinase (FAK or EC 2.7.10.2) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Focal Adhesion Kinase (FAK or EC 2.7.10.2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Focal Adhesion Kinase (FAK or EC 2.7.10.2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Asana BioSciences, LLC

Boehringer Ingelheim GmbH

GlaxoSmithKline Plc

Takeda Pharmaceutical Company Limited

Teva Pharmaceutical Industries Ltd.

Verastem, Inc.

Asana BioSciences, LLC

Boehringer Ingelheim GmbH

GlaxoSmithKline Plc

Takeda Pharmaceutical Company Limited

Teva Pharmaceutical Industries Ltd.

Verastem, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Focal Adhesion ...

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Focal Adhesion Kinase (FAK or EC 2.7.10.2) Overview 7

Therapeutics Development 8

Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Products under Development by Stage of Development 8

Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Products under Development by Therapy Area 9

Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Products under Development by Indication 10

Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Pipeline Products Glance 12

Late Stage Products 12

Early Stage Products 13

Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Products under Development by Companies 14

Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Products under Development by Universities/Institutes 17

Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Therapeutics Assessment 19

Assessment by Monotherapy/Combination Products 19

Assessment by Mechanism of Action 20

Assessment by Route of Administration 22

Assessment by Molecule Type 24

Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Companies Involved in Therapeutics Development 25

Asana BioSciences, LLC 25

Boehringer Ingelheim GmbH 26

GlaxoSmithKline Plc 27

Takeda Pharmaceutical Company Limited 28

Teva Pharmaceutical Industries Ltd. 29

Verastem, Inc. 30

Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Drug Profiles 31

ASN-006 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

BI-853520 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

CEP-37440 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

cilengitide - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

CT-707 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

CTX-0294886 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

CTX-0294945 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

defactinib hydrochloride - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

GSK-2256098 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Small Molecule to Inhibit Focal Adhesion Kinase for Solid Tumors - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Small Molecules to Inhibit FAK for Oncology - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Small Molecules to Inhibit Focal Adhesion Kinase for Oncology - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

VS-4718 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

VS-6062 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Dormant Projects 56

Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Discontinued Products 58

Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Featured News & Press Releases 59

Jul 05, 2016: Study Published in Nature Medicine Highlights Potential Role of FAK Inhibition in Pancreatic Cancer 59

May 25, 2016: Iceni Pharmaceuticals launches as new company focusing on repurposing therapies in the field of oncology 60

May 04, 2016: Verastem Announces the Presentation of Clinical Data at iMig 2016 61

Mar 30, 2016: Verastem Announces Presentation of Scientific Data Supporting FAK Inhibition in Combination with Immunotherapy at the Keystone Symposium on Cancer Pathophysiology 61

Mar 16, 2016: Verastem to Present Data Supporting FAK/PYK2 Inhibition at the 2016 American Academy of Cancer Research Annual Meeting 62

Mar 16, 2016: Verastem to present data supporting FAK inhibition at the 2016 American Academy of cancer research annual meeting 63

Jan 21, 2016: Verastem to Present Scientific Data Supporting FAK Inhibition in Combination with Immune Checkpoint Inhibitors at Immunotherapy World 2016 64

Jan 06, 2016: Washington University in St. Louis Initiates Clinical Study of Verastem’s VS-6063 in Combination with Merck’s Pembrolizumab and Gemcitabine in Pancreatic Cancer 65

Sep 28, 2015: Verastem Stops Enrollment Due to Futility in the Command Study of Vs-6063 for the Treatment of Malignant Pleural Mesothelioma 66

Sep 17, 2015: Verastem Announces Presentation On VS-6063 at ESMO/ECCO 2015 66

Sep 10, 2015: Verastem Presents Clinical and Preclinical Data at the 16th World Conference on Lung Cancer 67

Aug 26, 2015: Verastem to Present Data at the 16th World Conference on Lung Cancer 68

Dec 11, 2014: Verastem Presents Data at the 2014 San Antonio Breast Cancer Symposium 69

Dec 04, 2014: Verastem to Present Data on VS-6063 at the 2014 San Antonio Breast Cancer Symposium 70

Dec 04, 2014: Verastem to Present Data on VS-4718 at the 2014 San Antonio Breast Cancer Symposium 70

Appendix 71

Methodology 71

Coverage 71

Secondary Research 71

Primary Research 71

Expert Panel Validation 71

Contact Us 71

Disclaimer 72

List of Tables

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of ...

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Products under Development by Companies, H2 2016 15

Products under Development by Companies, H2 2016 (Contd..1) 16

Number of Products under Investigation by Universities/Institutes, H2 2016 17

Products under Investigation by Universities/Institutes, H2 2016 18

Assessment by Monotherapy/Combination Products, H2 2016 19

Number of Products by Stage and Mechanism of Action, H2 2016 21

Number of Products by Stage and Route of Administration, H2 2016 23

Number of Products by Stage and Molecule Type, H2 2016 24

Pipeline by Asana BioSciences, LLC, H2 2016 25

Pipeline by Boehringer Ingelheim GmbH, H2 2016 26

Pipeline by GlaxoSmithKline Plc, H2 2016 27

Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 28

Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016 29

Pipeline by Verastem, Inc., H2 2016 30

Dormant Projects, H2 2016 56

Dormant Projects (Contd..1), H2 2016 57

Discontinued Products, H2 2016 58

List of Figures

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Top 10 Indication, H2 2016 10

Comparative ...

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Top 10 Indication, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 19

Number of Products by Mechanism of Actions, H2 2016 20

Number of Products by Stage and Mechanism of Actions, H2 2016 20

Number of Products by Routes of Administration, H2 2016 22

Number of Products by Stage and Routes of Administration, H2 2016 22

Number of Products by Stage and Molecule Type, H2 2016 24

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports